Abstract
MCL-1 protein belongs to the Bcl-2 family consisting of both pro- and anti-apoptotic proteins. It serves as a master pro-survival factor by inhibiting apoptosis in a broad range of human malignancies. MCL-1 is involved in cancer resistance to different types of therapies, thus its targeting appears very attractive. Although several MCL-1 inhibitors have been studied in clinical trials, none has been approved for clinical use so far. Degradation of a target protein offers several advantages over traditional inhibitors, e.g.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
